Display options
Cite
Udwadia ZF, Vora A, Tripathi AR, et al. COVID-19 -Tuberculosis interactions: When dark forces collide. Indian J Tuberc. 2020;67(4):S155-S162doi: 10.1016/j.ijtb.2020.07.003.
Udwadia, Z. F., Vora, A., Tripathi, A. R., Malu, K. N., Lange, C., & Sara Raju, R. (2020). COVID-19 -Tuberculosis interactions: When dark forces collide. The Indian journal of tuberculosis, 67(4), S155-S162. https://doi.org/10.1016/j.ijtb.2020.07.003
Udwadia, Zarir F, et al. "COVID-19 -Tuberculosis interactions: When dark forces collide." The Indian journal of tuberculosis vol. 67,4 (2020): S155-S162. doi: https://doi.org/10.1016/j.ijtb.2020.07.003
Udwadia ZF, Vora A, Tripathi AR, Malu KN, Lange C, Sara Raju R. COVID-19 -Tuberculosis interactions: When dark forces collide. Indian J Tuberc. 2020 Dec;67(4):S155-S162. doi: 10.1016/j.ijtb.2020.07.003. Epub 2020 Jul 15. PMID: 33308662; PMCID: PMC7362784.
Copy Download .nbib Format: NLM
Share it on

Indian J Tuberc. 2020 Dec;67(4):S155-S162. doi: 10.1016/j.ijtb.2020.07.003. Epub 2020 Jul 15.

COVID-19 -Tuberculosis interactions: When dark forces collide.

The Indian journal of tuberculosis

Zarir F Udwadia, Agam Vora, Awatansh R Tripathi, Ketan N Malu, Christoph Lange, Reyma Sara Raju

Affiliations

  1. P.D. Hinduja Hospital and Medical Research Centre, Mumbai, India. Electronic address: [email protected].
  2. Advanced Multispecialty Hospital, Mumbai, India.
  3. P.D. Hinduja Hospital and Medical Research Centre, Mumbai, India.
  4. Clinical Infectious Diseases, Research Center Borstel, Borstel, 23845, Germany.

PMID: 33308662 PMCID: PMC7362784 DOI: 10.1016/j.ijtb.2020.07.003

Abstract

The SARS-2 pandemic which has moved with frightening speed over the last 5 months has several synergies with another older, and far more neglected airborne disease, tuberculosis. Patients with tuberculosis are not only more likely to be infected by SARS-CoV-2 but also likely to have adverse outcomes once infected. The sequelae of more severe forms of COVID-19 in patients who have recovered from TB but have residual compromised lung function, are also likely to be devastating. These diseases share almost identical bio-social determinants like poverty, overcrowding, diabetes and pollution and some clinical similarities. The consequences of the COVID-19 pandemic, and our global response to it with lockdowns, are likely to leave a profound and long-lasting impact on TB diagnosis and control, potentially leading to an additional 6.3 million cases of TB between 2020 and 2025, and an additional 1.4 million TB deaths during this time. Novel solutions will need to be urgently devised or else TB control targets will never be met and indeed may be set back by 5-8 years.

Copyright © 2020 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.

Keywords: COVID-19; MDR-TB; SARS-CoV-2; Synergistic effects; Tuberculosis

References

  1. J Antimicrob Chemother. 2016 Apr;71(4):1037-40 - PubMed
  2. Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5 - PubMed
  3. Sci Total Environ. 2020 Jul 15;726:138605 - PubMed
  4. Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403 - PubMed
  5. Front Immunol. 2020 May 01;11:827 - PubMed
  6. JAMA. 2020 Jun 9;323(22):2249-2251 - PubMed
  7. N Engl J Med. 2020 Jul 17;: - PubMed
  8. Vaccine. 2013 Feb 18;31(9):1340-8 - PubMed
  9. PLoS One. 2012;7(9):e44793 - PubMed
  10. Clin Infect Dis. 2015 Jun 1;60(11):1611-9 - PubMed
  11. Indian J Tuberc. 2019 Jan;66(1):178-183 - PubMed
  12. Int J Infect Dis. 2020 May;94:91-95 - PubMed
  13. Lancet Infect Dis. 2020 May;20(5):565-574 - PubMed
  14. N Engl J Med. 2020 Nov 5;383(19):1813-1826 - PubMed
  15. Radiology. 2020 Aug;296(2):E55-E64 - PubMed

MeSH terms

Publication Types